Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer-Reference-Cited by-同舟云学术

Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer

Published:2019-03-27 Issue:6 Volume:8 Page:e1593810
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Hardy-Werbin Max¹²,Rocha Pedro³,Arpi Oriol¹,Taus Álvaro³,Nonell Lara⁴,Durán Xavier⁵,Villanueva Xavier³,Joseph-Pietras Deborah⁶,Nolan Luke⁷,Danson Sarah⁸,Griffiths Richard⁹,Lopez-Botet Miguel¹⁰¹¹,Rovira Ana¹³,Albanell Joan¹³¹¹,Ottensmeier Christian⁶¹²,Arriola Edurne¹³

Affiliation:

1. Cancer Research Program, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), Barcelona, Spain

2. Universitat de Barcelona, Barcelona, Spain

3. Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain

4. Microarrays analysis service, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), Barcelona, Spain

5. Statistics department, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), Barcelona, Spain

6. NIHR Experimental Cancer Medicine Centre, Southampton, UK

7. Medical Oncology Department, University Hospital Southampton, Southampton, UK

8. Sheffield Experimental Cancer Medicine Centre, Weston Park Hospital, Sheffield, UK

9. The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK

10. Immunology unit, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), Barcelona, Spain

11. Universitat Pompeu Fabra, Barcelona, Spain

12. Cancer Science Unit, Faculty of Medicine, University of Southampton, Southampton, UK

Funder

Agència de Gestió d’Ajuts Universitaris i de Recerca

Fundació la Marató de TV3

Fundación Cellex

Instituto de Salud Carlos III

Cancer Research UK Grant

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2019.1593810

Reference46 articles.

1. Twenty-Seven Years of Phase III Trials for Patients with Extensive Disease Small-Cell Lung Cancer: Disappointing Results

2. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

3. Paraneoplastic Syndromes Involving the Nervous System

4. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer;Cell & Bioscience;2024-09-12

2. Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours;Clinical and Translational Medicine;2024-08

3. Prognostic impact of Interleukin-8 levels in lung cancer: A meta-analysis and a bioinformatic validation;Lung Cancer;2024-08

4. Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series;RMD Open;2024-08

5. Serum interleukin‐6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis;Journal of Gastroenterology and Hepatology;2024-06-28